

Long COVID brain fog and muscle pain are associated with longer time to clearance of SARS-CoV-2 RNA from the upper respiratory tract during acute infection

Annukka A. R. Antar^{1*}, Tong Yu¹, Zoe O Demko¹, Chen Hu², Jeffrey A. Tornheim¹, Paul W. Blair³, David L. Thomas¹, Yukari C. Manabe¹, OutSMART Study Group

¹Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, MD, United States

²Department of Oncology, Johns Hopkins University School of Medicine, Baltimore, MD, United States

³Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc., Bethesda, MD, United States

* **Correspondence:** Dr. Annukka Antar, aaantar1@jhmi.edu

Keywords: COVID-19, Long COVID, Post-Acute COVID-19 Syndrome, Post-Acute Sequelae of SARS-CoV-2 infection, Brain fog, Cognitive Dysfunction, Pain, Reservoir

Abstract

The incidence of long COVID is substantial, even in people who did not require hospitalization for acute COVID-19. The pathobiological mechanisms of long COVID and the role of early viral kinetics in its development are largely unknown. Seventy-three non-hospitalized adult participants were enrolled within approximately 48 hours of their first positive SARS-CoV-2 RT-PCR test, and mid-turbinate nasal and saliva samples were collected up to 9 times within the first 45 days after enrollment. Samples were assayed for SARS-CoV-2 using RT-PCR and additional test results were abstracted from the clinical record. Each participant indicated the presence and severity of 49 long-COVID symptoms at 1-, 3-, 6-, 12-, and 18-months post-COVID-19 diagnosis. Time from acute COVID-19 illness onset to SARS-CoV-2 RNA clearance greater or less than 28 days was tested for association with the presence or absence of each of 49 long COVID symptoms at 90+ days from acute COVID-19 symptom onset. Brain fog and muscle pain at 90+ days after acute COVID-19 onset were negatively associated with viral RNA clearance within 28 days of acute COVID-19 onset with adjustment for age, sex, BMI ≥ 25 , and COVID vaccination status prior to COVID-19 (brain fog: aRR 0.46, 95% CI 0.22-0.95; muscle pain: aRR 0.28, 95% CI 0.08-0.94). This work indicates that at least two long COVID symptoms - brain fog and muscle pain – at 90+ days from acute COVID-19 onset are specifically associated with longer time to clearance of SARS-CoV-2 RNA from the upper respiratory tract.

Introduction

The incidence of long COVID is substantial, even in people who did not require hospitalization for acute COVID-19 (1). The United States Census Household Pulse Survey of December 2022 estimates that 28% of U.S. adults who ever had COVID-19 experienced long COVID symptoms lasting 3 months or longer (2). Among the most common and debilitating symptoms are pain and a lack of mental clarity or problems with concentration, also called “brain fog” (3, 4). Viral antigen persistence in tissues may be one mechanism of long COVID (5, 6). However, few longitudinal studies with well-characterized viral dynamics in the acute phase have assessed the relationship between viral persistence and long COVID symptoms, especially in people with mild to moderate acute COVID-19 who represent typical disease severity in the general population. Here we examine the association between time to viral RNA clearance from the upper respiratory tract (URT) during acute COVID-19 and specific clinical symptoms of long COVID at 90 or more days from acute COVID-19 illness onset in a cohort of people diagnosed with symptomatic COVID-19 in the outpatient setting.

Methods

A convenience sample of non-hospitalized adults with a first positive SARS-CoV-2 PCR test within the previous 48 hours from the Johns Hopkins Health System and their household contacts were prospectively enrolled between April 21, 2020, and October 28, 2021 (7). Participants provided verbal consent after documentation of understanding, using a consent waiver with an alteration of informed consent, as most were isolating or quarantining at home. The study was conducted in either English or Spanish. This study protocol and verbal consent were approved by the Johns Hopkins University School of Medicine Institutional Review Board.

Mid-turbinate nasal swabs and saliva (URT samples) were collected at 1, 3, 7, 10, 14, 21, 28, 35, and 42 days from enrollment. Mid-turbinate nasal swabs were collected in 600 μ L volumes of viral transport media, and 200 μ L volumes of saliva were collected. Collections at 1, 3, 7, 10, 14, 21, 35, and 42 days after study enrollment were self-collected into study-provided vials with guidance by phone or video call from study staff and frozen immediately. Collections at 28 days after study enrollment were performed primarily in-person at a research clinic visit with study staff guiding or performing collection. SARS-CoV-2 RT-PCR testing was performed on all samples (Abbott *m2000* platform, Abbott Park, IL, USA) per manufacturer instructions as described previously (8). Discordant results from samples collected on the same day (e.g. positive nasal, negative saliva) were recorded as URT positive. Adequacy of self-collected samples was confirmed via RT-PCR for *gapDH* human gene expression utilizing a TaqMan gene expression assay for the first 1338 samples (8). Briefly, eluates from the Abbott *m2000* were analyzed by the NanoDrop One (ThermoFisher Scientific, Waltham, MA) to determine total RNA concentration and all samples were normalized to 1 ng/ μ L of total RNA prior to analysis for *gapDH*. Normalized samples were utilized to synthesize cDNA in 10 μ L volumes utilizing Superscript IV RT (ThermoFisher) per manufacturer instructions. Post cDNA synthesis, samples were assessed for the presence of *gapDH* utilizing RT-PCR (Applied Biosystems, Foster City, CA) per manufacturer instructions. Positive reactions were defined as reactions having a cycle threshold value < 40 . 1227 of 1338 self-collected samples were positive for human *gapDH*, and all negative reactions started from eluates with $< 1 \mu$ L, indicating insufficient material for NanoDrop analysis or cDNA synthesis. COVID-19 PCR testing results from the clinical electronic medical records were also included in this analysis.

At 1, 3, 6, 12, and 18 months post-COVID-19 diagnosis, participants were asked, “Have you had any of the following symptoms in the past week?” and selected one of “Not at all”, “A little bit”, “Somewhat”, “Very much”, or “Quite a bit” for each of 49 long COVID symptoms (Table 1). Thirty-eight symptoms derive from the FLU-PRO[®] Plus (9), and eleven additional symptoms were added based on frequency of report in a Long COVID Patient-Led Research Collaborative survey with input from the patient-researcher authors (3). Similar to the other symptoms, brain fog was assessed with the question “Have you had problems with concentration or ‘brain fog’ in the past week?”

Time to SARS-CoV-2 RNA clearance was defined as the number of days between acute COVID-19 symptom/illness onset (recorded at study enrollment) and the midpoint between a participant’s last positive URT RNA test and the following negative URT PCR test. Time to viral RNA clearance was classified as a binary variable: within or beyond 28 days. For each of 49 long COVID symptoms, we estimated the relative risk of reporting that symptom 90+ days from acute COVID-19 onset by time to viral RNA clearance within 28 days using log-binomial regression (10) and adjusting for age, sex, BMI over/under 25, and COVID vaccination status prior to acute COVID-19 (1+ vaccines vs. none) (StataSE 17, StataCorp).

Results

Seventy-three participants with symptomatic, PCR-confirmed acute COVID-19, age ≥ 18 , with ≥ 2 URT samples within 28 days of enrollment, and who completed at least one comprehensive symptom survey ≥ 90 days from acute COVID-19 onset were included in this analysis. The participants had a median of three study days with a positive PCR test prior to a study day with a negative PCR test, and 75% of participants had ≥ 5 study days with PCR tests available for analysis. The median time to viral RNA clearance was 17 days for the 51 participants who had a negative PCR test within 21 days of their last positive PCR test (interquartile ratio, IQR, 14.75-22.75).

The median age of participants was 52 years (IQR, 42-60), 63% were women, 27% self-reported as non-Hispanic African American, 52% self-reported as non-Hispanic White, and 16% self-reported as Hispanic (Table 2). All participants tested positive for COVID-19 in the outpatient setting, and two (2.7%) ultimately required hospitalization during acute COVID-19. Of the participants, 81% were unvaccinated prior to COVID-19, 5% had incomplete primary vaccine series, and 14% had received a complete primary vaccine series prior to COVID-19 (Table 2).

The association of the presence of each of 49 long COVID symptoms (Table 1) at 90+ days post-acute COVID-19 onset with time to SARS-CoV-2 RNA clearance from the URT within 28 days was first tested without adjustment using log-binomial regression analyses. Eleven symptoms with p values < 0.2 were tested using log-binomial regression analyses with adjustment for age, sex, BMI ≥ 25 , and COVID vaccination status prior to acute COVID-19. Brain fog and muscle pain at 90+ days after acute COVID-19 illness onset were negatively associated with viral RNA clearance within 28 days with these adjustments (Figure, brain fog: aRR 0.46, 95% CI 0.22-0.95; muscle pain: aRR 0.28, 95% CI 0.08-0.94). The model failed to converge for two rarely reported symptoms, leg swelling and problems with balance. Leg swelling at 90+ days from acute COVID-19 onset was negatively associated with viral RNA clearance within 28 days of acute COVID-19 onset in an unadjusted analysis (RR 0.17, 95% CI 0.04-0.76) and in an analysis adjusted only for age and sex (aRR 0.21, 95% CI 0.05-0.82). Problems with balance at 90+ days from acute COVID-19 onset was negatively associated with viral RNA clearance within 28 days of acute COVID-19 onset only in an analysis adjusted for age, sex, and vaccination status (aRR 0.47, 95% CI 0.25-0.90) but not in a univariate analysis. There were nonsignificant trends towards negative associations of body aches or pain,

anxiety, confusion, and sweating with viral RNA clearance within 28 days after adjustment for age, sex, BMI ≥ 25 , and COVID vaccination status prior to acute COVID-19 (Figure). No other associations of long COVID symptoms with viral RNA clearance time within 28 days reached statistical significance.

Discussion

We demonstrate here that post-acute brain fog and muscle pain are associated with prolonged time to clearance of SARS-CoV-2 RNA from the upper respiratory tract during acute COVID-19. This finding provides evidence that delayed immune clearance of SARS-CoV-2 antigen and/or greater amount or duration of viral antigen burden in the upper respiratory tract during acute COVID-19 is directly linked to long COVID. This work indicates that host-pathogen interactions during the first few weeks after COVID-19 symptom have in impact on long COVID risk months later.

Currently, the biological mechanisms underlying long COVID and its myriad symptoms are unclear. There are several different hypotheses: persistent immune dysregulation following acute COVID-19, persistent SARS-CoV-2 virions or antigen (“reservoirs”) triggering chronic inflammation, reactivation of other viruses such as Epstein-Barr virus (EBV), autoimmunity triggered by acute illness, endothelial dysfunction and/or microthrombi impairing organ function, metabolic or mitochondrial dysfunction on the cellular level, autonomic nervous system injury, lingering or evolving organ injury from acute COVID-19, and microbiota alterations, among others (11). A recent comprehensive autopsy study provided evidence for an early viremic phase during acute COVID-19 that spreads infectious virus throughout the body and demonstrated convincingly that SARS-CoV-2 RNA can persist for >30 days in multiple extrapulmonary sites (12).

There have been a few studies that link long COVID with persistent SARS-CoV-2 antigen detected in the late post-acute time period, notably spike protein in plasma (13), SARS-CoV-2 proteins in plasma neuron- and astrocyte-derived extracellular vesicles (14), spike protein in monocytes (15), and fecal RNA shedding (16). However, there has been just one study to our knowledge linking virus kinetics or detection during acute COVID-19 with long COVID; this study associated the presence or absence of SARS-CoV-2 RNA in the plasma at the time of COVID-19 diagnosis and hospitalization with one or more symptoms of long COVID several months later (17). However, this study was limited to people with severe acute COVID-19 (17), and it may be that the presence of SARS-CoV-2 RNA-emia at hospital presentation is an indicator of the severity of acute COVID-19, which is already known to be a risk factor for long COVID (1).

Our study provides robust support to the hypothesis that viral kinetics during the acute phase of illness is associated with long COVID by using frequent longitudinal sampling beginning within days of acute COVID-19 onset to determine the duration of viral RNA shedding from the URT. Additionally, since long COVID may comprise one or more syndromes with unique mechanisms, we assessed individual symptoms from multiple organs or domains affected by long COVID to determine whether particular syndromes or symptom clusters of long COVID are associated with viral kinetics in the acute phase. We studied a population that primarily had mild-moderate COVID-19 and thus is more representative of the general population of people who had COVID-19 or long COVID and limits the amount by which severity of acute illness could confound our results. A final strength of this cohort is the racial and ethnic diversity of participants. A weakness of the study is that the intensity of study coordination involved in repeated longitudinal sampling and follow-up in acute and post-acute COVID-19 limited the number of participants enrolled.

Our data are consistent with a few biologically plausible scenarios. First, both delayed clearance of viral antigen and long COVID are caused by another factor such as dysregulated or distracted immunity. This dysregulated immunity might cause long COVID by reactivating other latent viruses, triggering autoimmunity, causing direct organ damage, or delaying tissue repair from acute infection. Second, persistent expression of viral antigens, and/or a larger burden of initial antigen, might directly cause long COVID by sustaining tissue injury and inflammation. The latter mechanism is supported by early studies linking antiviral treatment of people during acute COVID-19 with reduced incidence of long COVID (18). More studies with longitudinal repeated sampling beginning from acute COVID-19 illness treated with and without antivirals through the post-acute phase are urgently needed to assess how host-pathogen interactions lead to long COVID.

Here we report that at least two long COVID symptoms - brain fog and muscle pain – at 90+ days from acute COVID-19 onset are specifically associated with longer time to clearance of SARS-CoV-2 RNA from the upper respiratory tract during acute illness.

Conflict of Interest

Dr. Manabe has received research grant support to Johns Hopkins University from Hologic, Cepheid, Roche, ChemBio, Becton Dickinson, miDiagnostics, and has provided consultative support to Abbott, none of which constitute a conflict of interest with this study. No other authors have commercial or financial relationships that could be construed as a potential conflict of interest.

Author Contributions

AA, TY, YM: conception and design. AA, TY, CH: statistical analysis and interpretation of data. PB, YM: obtained funding. DT, YM: administrative, technical, or material support. All authors: writing, review, and critical revision of the manuscript for important intellectual content. AA, YM: study supervision.

Funding

Drs Blair and Manabe received support for this work from the Henry M. Jackson Foundation for the Advancement of Military Medicine (contract number 1007957) and the Sherrilyn and Ken Fisher Center for Environmental Infectious Diseases Discovery Program. Dr. Antar is supported by the National Institutes of Health (grant number K08AI143391).

OutSMART Study Group

M. Gabriela Varela Heslin, Sarika K. Mullapudi, Chamia Dorsey, Christine Payton, Sidney-Saint-Hilaire, Zihan Yang, Justin Chan, Razvan Azamfirei, Minyoung Jang, Taylor Church, Carolyn Reuland, Vismaya S. Bachu, Jennifer L. Townsend, Sara C. Keller, Jeanne C. Keruly, Justin P. Hardick, Madison Conte, and Thelio Sewell.

Acknowledgments

We express gratitude for all the participants who donated time and samples for this study. We thank the following individuals for their assistance with this study: Diane M. Brown, Brittany Barnaba, Curtisha Charles, Michelle Prizzi, Oyinkansola Kusemiju, and Jaylynn R. Johnstone.

References

1. Xie Y, Bowe B, Al-Aly Z. Burdens of Post-Acute Sequelae of Covid-19 by Severity of Acute Infection, Demographics and Health Status. *Nat Commun* (2021) 12(1):6571. Epub 2021/11/14. doi: 10.1038/s41467-021-26513-3.
2. Statistics NCfH. Long Covid Household Pulse Survey (2023) [updated 01/05/2023; cited 2023 01/09/2023]. Available from: <https://www.cdc.gov/nchs/covid19/pulse/long-covid.htm>.
3. Davis HE, Assaf GS, McCorkell L, Wei H, Low RJ, Re'em Y, et al. Characterizing Long Covid in an International Cohort: 7 Months of Symptoms and Their Impact. *EClinicalMedicine* (2021) 38:101019. Epub 2021/07/27. doi: 10.1016/j.eclinm.2021.101019.
4. Ceban F, Ling S, Lui LMW, Lee Y, Gill H, Teopiz KM, et al. Fatigue and Cognitive Impairment in Post-Covid-19 Syndrome: A Systematic Review and Meta-Analysis. *Brain Behav Immun* (2022) 101:93-135. Epub 2022/01/02. doi: 10.1016/j.bbi.2021.12.020.
5. Brodin P, Casari G, Townsend L, O'Farrelly C, Tancevski I, Loffler-Ragg J, et al. Studying Severe Long Covid to Understand Post-Infectious Disorders Beyond Covid-19. *Nat Med* (2022) 28(5):879-82. Epub 2022/04/07. doi: 10.1038/s41591-022-01766-7.
6. Mehandru S, Merad M. Pathological Sequelae of Long-Haul Covid. *Nat Immunol* (2022) 23(2):194-202. Epub 2022/02/03. doi: 10.1038/s41590-021-01104-y.
7. Blair PW, Brown DM, Jang M, Antar AAR, Keruly JC, Bachu VS, et al. The Clinical Course of Covid-19 in the Outpatient Setting: A Prospective Cohort Study. *Open Forum Infect Dis* (2021) 8(2):ofab007. Epub 2021/02/23. doi: 10.1093/ofid/ofab007.
8. Antar AAR, Yu T, Pisanic N, Azamfirei R, Tornheim JA, Brown DM, et al. Delayed Rise of Oral Fluid Antibodies, Elevated Bmi, and Absence of Early Fever Correlate with Longer Time to Sars-Cov-2 Rna Clearance in a Longitudinally Sampled Cohort of Covid-19 Outpatients. *Open Forum Infect Dis* (2021) 8(6):ofab195. Epub 2021/06/08. doi: 10.1093/ofid/ofab195.
9. Richard SA, Epsi NJ, Pollett S, Lindholm DA, Malloy AMW, Maves R, et al. Performance of the Influenza Patient-Reported Outcome Plus (Flu-Pro Plus) Instrument in Patients with Coronavirus Disease 2019. *Open Forum Infect Dis* (2021) 8(12):ofab517. Epub 2021/12/14. doi: 10.1093/ofid/ofab517.
10. Wacholder S. Binomial Regression in Glim: Estimating Risk Ratios and Risk Differences. *Am J Epidemiol* (1986) 123(1):174-84. Epub 1986/01/01. doi: 10.1093/oxfordjournals.aje.a114212.
11. Castanares-Zapatero D, Chalon P, Kohn L, Dauvrin M, Detollenaere J, Maertens de Noordhout C, et al. Pathophysiology and Mechanism of Long Covid: A Comprehensive Review. *Ann Med* (2022) 54(1):1473-87. Epub 2022/05/21. doi: 10.1080/07853890.2022.2076901.
12. Stein SR, Ramelli SC, Grazioli A, Chung JY, Singh M, Yinda CK, et al. Sars-Cov-2 Infection and Persistence in the Human Body and Brain at Autopsy. *Nature* (2022) 612(7941):758-63. Epub 2022/12/15. doi: 10.1038/s41586-022-05542-y.
13. Swank Z, Senussi Y, Manickas-Hill Z, Yu XG, Li JZ, Alter G, et al. Persistent Circulating Sars-Cov-2 Spike Is Associated with Post-Acute Covid-19 Sequelae. *Clin Infect Dis* (2022). Epub 2022/09/03. doi: 10.1093/cid/ciac722.

14. Peluso MJ, Deeks SG, Mustapic M, Kapogiannis D, Henrich TJ, Lu S, et al. Sars-Cov-2 and Mitochondrial Proteins in Neural-Derived Exosomes of Covid-19. *Ann Neurol* (2022) 91(6):772-81. Epub 2022/03/15. doi: 10.1002/ana.26350.
15. Patterson BK, Francisco EB, Yogendra R, Long E, Pise A, Rodrigues H, et al. Persistence of Sars Cov-2 S1 Protein in Cd16+ Monocytes in Post-Acute Sequelae of Covid-19 (Pasc) up to 15 Months Post-Infection. *Front Immunol* (2021) 12:746021. Epub 2022/01/28. doi: 10.3389/fimmu.2021.746021.
16. Natarajan A, Zlitni S, Brooks EF, Vance SE, Dahlen A, Hedlin H, et al. Gastrointestinal Symptoms and Fecal Shedding of Sars-Cov-2 Rna Suggest Prolonged Gastrointestinal Infection. *Med (N Y)* (2022) 3(6):371-87 e9. Epub 2022/04/19. doi: 10.1016/j.medj.2022.04.001.
17. Su Y, Yuan D, Chen DG, Ng RH, Wang K, Choi J, et al. Multiple Early Factors Anticipate Post-Acute Covid-19 Sequelae. *Cell* (2022) 185(5):881-95 e20. Epub 2022/02/27. doi: 10.1016/j.cell.2022.01.014.
18. Xie YC, T.; Al-Aly, Z. Nirmatrelvir and the Risk of Post-Acute Sequelae of Covid-19. *medRxiv* (2022). Epub 11/05/2022. doi: <https://doi.org/10.1101/2022.11.03.22281783>

TABLE 1. List of 49 long COVID symptoms assessed in surveys 1, 3, 6, 12, and 18 months from enrollment. Participants were asked, “Have you had any of the following symptoms in the past week?” and selected one of “Not at all”, “A little bit”, “Somewhat”, “Very much”, or “Quite a bit” for each symptom.

Category	Symptom
Body/Systemic	Fever (>100.4 F / >38.0 C or suspected but temperature unknown)
	Low grade fever (99.0-100.3 F / 37.2-37.9 C)
	Chills or shivering
	Felt cold
	Felt hot
	Sweating
	Head congestion
	Constant thirst
	Lack of appetite
	Body aches or pain
	Joint pain
	Muscle pain
	Leg swelling
	Sleeping more than usual
	Trouble sleeping or insomnia
Weak or tired or fatigued	
Neurologic	Headache
	Felt dizzy
	Problems with balance
	Confusion
	Memory problems
	Problems with concentration or “brain fog”
	Seizure
	Hallucinations or lucid dreaming
Anxiety	
Ringling in ears	
Eye	Teary or watery eyes
	Sore or painful eyes

	Eyes sensitive to light
Nose	Runny or dripping nose Congested or stuffy nose Sinus pressure
Throat	Scratchy or itchy throat Sore or painful throat Difficulty swallowing
Chest/Respiratory	Trouble breathing/shortness of breath Dry or hacking cough Wet or loose cough Chest congestion Chest pain or pressure, chest tightness or burning in chest Heart palpitations; funny or fast heartbeat
Smell/Taste	Full or partial loss of taste Full or partial loss of smell
Gastrointestinal	Felt nauseous (feeling like you want to throw up) Vomiting Stomach ache Diarrhea
Skin	Tingling, numbness, coldness, or other unusual sensation in skin Rash

TABLE 2. Participant demographics, body mass index, and pre-COVID vaccination status.

	Time to viral RNA clearance from URT^a > 28 days from acute COVID-19 onset (n=30)	Time to viral RNA clearance from URT^a ≤ 28 days from acute COVID-19 onset (n=43)
Age at enrollment, median (IQR), years	54 (46-65)	50 (40-58)
Female, no. (%)	18 (60)	28 (65)
Race & Ethnicity, no. (%)		
Non-Hispanic African American	9 (30)	11 (26)
Non-Hispanic White	15 (50)	23 (53)
Non-Hispanic other	1 (3)	2 (5)
Hispanic	5 (17)	7 (16)
BMI ≥ 25 kg/m ² , no. (%)	25 (83)	29 (67)
COVID vaccination status prior to COVID-19, no. (%)		
No vaccine doses	29 (97)	30 (70)
Incomplete primary vaccination series	0 (0)	4 (9)

Complete primary vaccination series	1 (3)	9 (21)
--	-------	--------

^aURT, upper respiratory tract encompassing mid-turbinate nasal swab and saliva

^bBMI, body mass index




FIGURE. The association of the presence of each of 49 long COVID symptoms at 90+ days after acute COVID-19 illness onset with SARS-CoV-2 RNA clearance from the upper respiratory tract (URT, mid-turbinate nasal and/or saliva) within 28 days from acute COVID-19 onset was tested without adjustment using log-binomial regression analyses. Nine long COVID symptoms with p values <0.2 were tested using log-binomial regression analyses with adjustment for age, sex, BMI over/under 25, and COVID vaccination status prior to acute COVID-19 (1+ vaccines vs none), with results shown here. aRR, adjusted risk ratio, d, day. ^aTingling, numbness, coldness, or other unusual sensation in skin.

Long COVID symptom	Number with long COVID symptom 90+ days from acute symptom onset		Association with clearance <28 d, aRR (95% CI)	Favors clearance ≥28 d	Favors clearance <28 d
	Viral RNA clearance ≥28 d (n=30)	Viral RNA clearance <28 d (n=43)			
Skin sensations ^a	5	2	0.25 (0.03-2.11)		
Muscle pain	10	5	0.28 (0.08-0.94)		
Confusion	7	3	0.32 (0.08-1.27)		
Problems with concentration or “brain fog”	14	11	0.46 (0.22-0.95)		
Sweating	8	6	0.47 (0.17-1.36)		
Body aches or pain	12	11	0.51 (0.22-1.20)		
Anxiety	10	8	0.52 (0.22-1.22)		
Trouble sleeping or insomnia	12	11	0.74 (0.37-1.50)		
Head congestion	4	12	1.87 (0.63-5.53)		

